Top Markets
#1 Black Phoenix Black Phoenix +17,837.96%
#2 Cash Dog in Hood Cash Dog in Hood +6,493.59%
#3 AgentFun.AI AgentFun.AI +54.83%
#4 up up +49.01%
#5 Arrow Arrow +48.53%
#6 Quai Network Quai Network +39.70%
#7 Octra Octra +37.04%
#8 Derive Derive +34.20%
#9 Block Street Block Street +31.33%
#10 B3 (Base) B3 (Base) +31.22%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Theranexus Société Anonyme Theranexus Société Anonyme

Theranexus Société Anonyme

ALTHX
Rank in Stocks #15061
Theranexus société anonyme, a biopharmaceutical company, develops drug... Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
Share Price
$4.66
Market Cap
$43.92M
Change (1 day)
-0.63%
Change (1 year)
338.04%
Country
FR
Trade Theranexus Société Anonyme (ALTHX)

Category

Healthcare
P/E ratio for Theranexus Société Anonyme (ALTHX)
P/E ratio as of July 2026 TTM: -15.09
According to Theranexus Société Anonyme latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -15.09. At the end of 2023 the company had a P/E ratio of -1.27.
P/E ratio history for Theranexus Société Anonyme from 2015 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -15.09 438.96%
2024 -2.80 119.64%
2023 -1.27 -10.15%
2022 -1.42 -52.63%
2021 -2.99 -81.07%
2020 -15.80 707.43%
2019 -1.96 -81.45%
2018 -10.55 -52.65%
2017 -22.27 154.85%
2016 -8.74 -67.31%
2015 -26.74 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 11.47 -175.97%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -293.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 14.66 -197.15%
US
UCB SA UCB SA
UCB SA
UCB.BR
 31.95 -311.72%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 51.86 -443.65%
NL
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.